Redmile Group »

4d Molecular Therapeutics In shares owned by Redmile Group

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by Redmile Group from 13F filings

Historical chart of Redmile Group investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by Redmile Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by Redmile Group

Quarter filed Position value Share count Share price at filing
2024-03-31 $40M 1.3M 31.86

More positions owned by Redmile Group

Krystal Biotech (KRYS)
Amicus Therapeutics (FOLD)
Immunome (IMNM)
Scholar Rock Hldg Corp (SRRK)
Fate Therapeutics (FATE)
Regenxbio Inc equity us cm (RGNX)
Deciphera Pharmaceuticals (DCPH)
Kymera Therapeutics (KYMR)
Adc Therapeutics Sa SHS (ADCT)
Stoke Therapeutics (STOK)
Augmedix (AUGX)
Nurix Therapeutics (NRIX)
Biohaven (BHVN)
Beam Therapeutics (BEAM)
Zymeworks Del (ZYME)

View all positions for Redmile Group

Top funds holding 4d Molecular Therapeutics In

RA Capital Management
VR Adviser
BlackRock
BVF
Henderson Group
Goldman Sachs Group
Deep Track Capital
Viking Global Investors
Vanguard Group
State Street Corporation
Polar Capital Holdings
Morgan Stanley
Novo A/S
Redmile Group
Arrowpoint Asset Management

View all funds holding 4d Molecular Therapeutics In